MediSix is an early-stage cell therapy company developing novel applications of chimeric antigen receptor (CAR) T-cell immunotherapies for T-cell leukemias and lymphomas. These indications typically have a poor prognosis and treatment options are limited as they are not amenable to existing CAR-T therapies. Scientific founder Dario Campana is considered a pioneer in the cell therapy space and his work has been instrumental in the development of much of the technology that exists today.